Biodesix (BDSX) financial statements
Biodesix reported revenue of $88M in fiscal 2025, up 23.8% a year over 6 years.
Net income was -$35M and the operating margin -31.5%, against -108.9% in 2019.
Free cash flow was -$24M.
The diluted share count rose 62305% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Biodesix's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $25M | $46M | $55M | $38M | $49M | $71M | $88M |
| Research and development | $10M | $11M | $13M | $13M | $10M | $10M | $12M |
| Selling, general and admin | $31M | $35M | $51M | $61M | $67M | $80M | $88M |
| Operating income | -$27M | -$23M | -$41M | -$51M | -$41M | -$34M | -$28M |
| Interest expense | $3M | $8M | $5M | $8M | $10M | $8M | $8M |
| Income tax | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$31M | -$65M | -$43M | -$65M | -$52M | -$43M | -$35M |
| EPS (diluted) | -$2,539.40 | -$129.60 | -$31.60 | -$31.00 | -$12.80 | -$6.64 | -$4.67 |
| Diluted shares | 0M | 0M | 1M | 2M | 4M | 6M | 8M |
| Operating margin | -108.9% | -50.3% | -75.1% | -132.4% | -84.2% | -48.4% | -31.5% |
| Net margin | -125.1% | -143.7% | -79.2% | -171.3% | -106.2% | -60.2% | -39.8% |
Balance sheet
Fiscal years, from Biodesix's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $5M | $62M | $33M | $43M | $26M | $26M | $19M |
| Receivables | $5M | $15M | $4M | $5M | $8M | $9M | $9M |
| Total current assets | $13M | $86M | $44M | $53M | $40M | $39M | $33M |
| Property, plant and equipment | $2M | $3M | $4M | $6M | $28M | $28M | $25M |
| Goodwill | $15M | $15M | $15M | $15M | $15M | $15M | $15M |
| Total assets | $45M | $121M | $76M | $93M | $99M | $97M | $87M |
| Total current liabilities | $23M | $32M | $29M | $23M | $33M | $14M | $17M |
| Total liabilities | $76M | $80M | $56M | $72M | $95M | $76M | $90M |
| Shareholders' equity | -$225M | $41M | $20M | $21M | $5M | $21M | -$2M |
| Net debt | -$5M | -$62M | -$33M | -$43M | -$26M | -$26M | -$19M |
Cash flow
Fiscal years, from Biodesix's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22M | -$21M | -$28M | -$45M | -$23M | -$49M | -$23M |
| Capital spending | $1M | $2M | $2M | $3M | $23M | $3M | $259,000 |
| Free cash flow | -$23M | -$23M | -$30M | -$48M | -$46M | -$52M | -$24M |
| Stock-based compensation | $170,000 | $4M | $5M | $6M | $5M | $7M | $4M |
| Net borrowing | — | — | -$45M | -$29M | -$49,000 | -$51,000 | -$21,000 |
| Free cash flow margin | -93.8% | -51.2% | -55.9% | -126.3% | -93.3% | -72.7% | -26.6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BDSX.
Open BDSX in InvestinglyQuestions
What was Biodesix's revenue in 2025?
$88M in fiscal 2025, from its 10-K filing.
How much free cash flow does Biodesix generate?
-$24M in fiscal 2025 (operating cash flow minus capital spending).
From Biodesix's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.